Patients with NASH-related HCC who received anti-PD-1 or anti-PD-L1 treatment have a lower overall survival rate than other HCC etiologies due to impaired immune surveillance [56]. Here, PDCD1 is linked to metabolic dysfunction-associated steatohepatitis.